- FTC Policy Paper Warns About Pitfalls of COPA Agreements for Patient Care and Healthcare Workers ( )
- FTC Action Against Benefytt Results in $100 Million in Refunds for Consumers Tricked into Sham Health Plans and Charged Exorbitant Junk Fees ( )
- Una acción de la FTC contra Benefytt da como resultado $100 millones de dólares en concepto de reembolsos para los consumidores engañados con planes de salud falsos y a los que les cobraron cargos basura exorbitantes ( )
- FTC Approves Final Order Protecting Pet Owners from Private Equity Firm’s Anticompetitive Acquisition of Veterinary Services Clinics ( )
- FTC Approves Final Order Preserving Competition for Development and Marketing of Steroid Injectable Drug ( )
- FTC Approves Final Order Protecting Patients Who Rely on Medical Instruments Used in Sinus Procedures ( )
- Federal Trade Commission Returns More Than $5.4 Million to Consumers ( )
- FTC Takes Second Action Against JAB Consumer Partners to Protect Pet Owners from Private Equity Firm’s Rollup of Veterinary Services Clinics ( )
- Statement of Bureau of Competition Director Holly Vedova Regarding the Decision of Utah Healthcare Competitors HCA Healthcare and Steward Health Care System to Abandon Their Proposed Merger ( )
- FTC to Ramp Up Enforcement Against Any Illegal Rebate Schemes, Bribes to Prescription Drug Middleman That Block Cheaper Drugs ( )
- FTC Acts to Protect Pet Owners from Private Equity Firm’s Anticompetitive Acquisition of Veterinary Services Clinics ( )
- FTC and Justice Department to Hold Two-Day Virtual Public Workshop Starting Tomorrow that Re-examines Antitrust Enforcement in the Pharmaceutical Industry ( )
- FTC Launches Inquiry Into Prescription Drug Middlemen Industry ( )
- FTC Sues to Block Merger Between Utah Healthcare Rivals HCA Healthcare and Steward Health Care System ( )
- FTC Sues to Block Merger Between New Jersey Healthcare Rivals RWJBarnabas Health and Saint Peter’s Healthcare System ( )
- FTC and Justice Department to Hold Two-Day Virtual Public Workshop Examining Antitrust Enforcement in the Pharmaceutical Industry ( )
- FTC Acts to Protect Patients Who Rely on Medical Instruments Used in Sinus Procedures ( )
- Federal Trade Commission Preserves Competition for Development and Marketing of Steroid Injectable Drug ( )
- Statement of Federal Trade Commission Bureau of Competition Deputy Director John M. Newman on Federal Appeals Court Ruling Affirming Preliminary Injunction to Halt Merger of New Jersey Hospital Networks ( )
- Statement Regarding Termination of Attempted Merger of Rhode Island’s Two Largest Healthcare Providers ( )
- FTC Approves Modifications to Boston Scientific Corp. Divestiture Agreement ( )
- FTC and Rhode Island Attorney General Step in to Block Merger of Rhode Island’s Two Largest Healthcare Providers ( )
- FTC Comment to Food and Drug Administration Supports Agency’s Proposed Rule on Establishing Over-the-Counter Hearing Aids ( )
- Vision Path, Inc., Online Seller of Hubble Lenses, Settles Charges it Violated the Contact Lens Rule and FTC Act to Boost Sales ( )
- With Omicron Variant on the Rise, FTC Orders More Marketers to Stop Falsely Claiming Their Products Can Effectively Prevent or Treat COVID-19 ( )
- Statement of Chair Lina M. Khan on the Ruling by Judge Denise L. Cote Federal Trade Commission et al v. Vyera Pharmaceuticals, LLC et al ( )
- FTC Approves Final Order Imposing Strict Limits on Future Mergers by Dialysis Service Provider DaVita, Inc. ( )
- FTC Approves Final Order Requiring Alabama Board of Dental Examiners to Stop Unreasonably Excluding Lower Cost Online and Teledentistry Providers from Competing ( )
- FTC, States to Recoup Millions in Relief for Victims Fleeced by ‘Pharma Bro’ Scheme to Illegally Monopolize Life-Saving Drug Daraprim ( )
- FTC Imposes Strict Limits on DaVita, Inc.’s Future Mergers Following Proposed Acquisition of Utah Dialysis Clinics ( )